Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216305%3A26620%2F24%3APU151616" target="_blank" >RIV/00216305:26620/24:PU151616 - isvavai.cz</a>
Alternative codes found
RIV/62156489:43210/24:43924829 RIV/62690094:18470/24:50021307 RIV/00179906:_____/24:10481310
Result on the web
<a href="https://www.eurekaselect.com/article/131443" target="_blank" >https://www.eurekaselect.com/article/131443</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/0929867330666230503144619" target="_blank" >10.2174/0929867330666230503144619</a>
Alternative languages
Result language
angličtina
Original language name
Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine
Original language description
The foundations of cell reprogramming were laid by Yamanaka and co-workers, who showed that somatic cells can be reprogrammed into pluripotent cells (induced pluripotency). Since this discovery, the field of regenerative medicine has seen advancements. For example, because they can differentiate into multiple cell types, pluripotent stem cells are considered vital components in regenerative medicine aimed at the functional restoration of damaged tissue. Despite years of research, both replacement and restoration of failed organs/ tissues have remained elusive scientific feats. However, with the inception of cell engineering and nuclear reprogramming, useful solutions have been identified to counter the need for compatible and sustainable organs. By combining the science underlying genetic engineering and nuclear reprogramming with regenerative medicine, scientists have engineered cells to make gene and stem cell therapies applicable and effective. These approaches have enabled the targeting of various pathways to reprogramme cells, i.e., make them behave in beneficial ways in a patient-specific manner. Technological advancements have clearly supported the concept and realization of regenerative medicine. Genetic engineering is used for tissue engineering and nuclear reprogramming and has led to advances in regenerative medicine. Targeted therapies and replacement of traumatized , damaged, or aged organs can be realized through genetic engineering. Furthermore, the success of these therapies has been validated through thousands of clinical trials. Scientists are currently evaluating induced tissue-specific stem cells (iTSCs), which may lead to tumour-free applications of pluripotency induction. In this review, we present state-of-the-art genetic engineering that has been used in regenerative medicine. We also focus on ways that genetic engineering and nuclear reprogramming have transformed regenerative medicine and have become unique therapeutic niches.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10609 - Biochemical research methods
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
CURRENT MEDICINAL CHEMISTRY
ISSN
0929-8673
e-ISSN
1875-533X
Volume of the periodical
31
Issue of the periodical within the volume
13
Country of publishing house
AE - UNITED ARAB EMIRATES
Number of pages
45
Pages from-to
1646-1690
UT code for WoS article
001229291300009
EID of the result in the Scopus database
2-s2.0-85184227820